Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.59 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5787593 | 0.83 | ALDH1A1 (0.59) | ALDH1A1GPR35HSD17B10KMT2ACYP3A4 | |
| SCHEMBL28030677 | 0.82 | KMT2A (0.61) | ALDH1A1GPR35HSD17B10KMT2ATSHR | |
| SCHEMBL11171104 | 0.79 | ALDH1A1 (0.48) | ALDH1A1GPR35HSD17B10KMT2ATSHR | |
| SCHEMBL3327506 | 0.79 | KMT2A (0.59) | ALDH1A1GPR35HSD17B10KMT2ATSHR | |
| SCHEMBL27262068 | 0.79 | ALDH1A1 (0.64) | ALDH1A1GPR35HSD17B10KMT2ATSHR | |
| SCHEMBL30717143 | 0.78 | ALDH1A1 (0.47) | ALDH1A1GPR35HSD17B10KMT2ATSHR | |
| SCHEMBL8099774 | 0.78 | ALDH1A1 (0.52) | ALDH1A1GPR35KMT2ATSHRCYP3A4 | |
| SCHEMBL9737315 | 0.77 | CA1 (0.67) | ALDH1A1GPR35HSD17B10KMT2ATSHR | |
| SCHEMBL5787676 | 0.77 | NR1H4 (0.52) | ALDH1A1GPR35HSD17B10KMT2ASMN1; SMN2 | |
| SCHEMBL27763193 | 0.77 | ALDH1A1 (0.52) | ALDH1A1GPR35HSD17B10KMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6855843-B2 | Inhibitors of α4 mediated cell adhesion | TANABE SEIYAKU CO., LTD. (JP) | 2005-02-15 | — | — | US | disclosed |
| US-20030191118-A1 | Inhibitors of alpha4 mediated cell adhesion | TANABE SEIYAKU CO., LTD. | 2003-10-09 | — | — | US | disclosed |
| US-6521666-B1 | Inhibitors of α4 mediated cell adhesion | TANABE SEIYAKU CO., LTD. (JP) | 2003-02-18 | — | — | US | disclosed |
| EP-1049662-A1 | INHIBITORS OF ALPHA4 MEDIATED CELL ADHESION | TANABE SEIYAKU CO., LTD. (JP) | 2000-11-08 | — | — | EP | disclosed |
| WO-1999036393-A1 | INHIBITORS OF α4 MEDIATED CELL ADHESION | TANABE SEIYAKU CO., LTD. (JP) | 1999-07-22 | — | — | WO | disclosed |
| US-4602041-A | TREATMENT OF DIARRHEA | BEECHAM GROUP P.L.C. (GB) | 1986-07-22 | — | — | US | disclosed |
| EP-0087218-B1 | GUANIDINE DERIVATIVES | BEECHAM GROUP PLC (GB) | 1985-05-02 | — | — | EP | disclosed |
| EP-0087218-A1 | Guanidine derivatives | BEECHAM GROUP PLC (GB) | 1983-08-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191118-A1 | Inhibitors of alpha4 mediated cell adhesion | ITGB4, ITGA4, VCAM1 | ALDH1A1 312/4885GPR35 2623/4885HSD17B10 2380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.